Provided by Tiger Trade Technology Pte. Ltd.

Faeth Therapeutics

35.37
-3.7200-9.52%
Post-market: 35.880.5100+1.44%19:53 EDT
Volume:209.39K
Turnover:7.67M
Market Cap:911.80M
PE:-0.25
High:39.89
Open:38.75
Low:34.88
Close:39.09
52wk High:42.14
52wk Low:7.45
Shares:25.78M
Float Shares:811.70K
Volume Ratio:0.68
T/O Rate:25.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-141.6499
EPS(LYR):-16.7239
ROE:-195.26%
ROA:-20.79%
PB:5.27
PE(LYR):-2.11

Loading ...

Faeth Therapeutics initiated with an Outperform at Baird

TIPRANKS
·
Jun 26

Top Faeth Therapeutics Insiders Quietly Double Down on the Company’s Future

TIPRANKS
·
Jun 25

Faeth Therapeutics CEO Anand Kiran Parikh Acquires $55,458.56 in Common Shares

Reuters
·
Jun 25

Faeth Therapeutics CFO Brian C. Stephenson files initial beneficial ownership statement

Reuters
·
Jun 24

Faeth Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 22

HC Wainwright Initiates Faeth Therapeutics at Buy With $60 Price Target

MT Newswires Live
·
Jun 22

Faeth Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

Faeth Therapeutics Launches New At-the-Market Equity Program

TIPRANKS
·
Jun 19

Sensei Biotherapeutics enters at-the-market equity distribution agreement for up to $150 million stock sale

Reuters
·
Jun 19

Faeth Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Jun 19

Faeth Therapeutics Enters Into Sales Agreement for Offering of up to $150 Mln

THOMSON REUTERS
·
Jun 19

Faeth Therapeutics, Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Jun 19

Sensei Biotherapeutics director Stephen M. Hahn files initial beneficial ownership statement

Reuters
·
Jun 17

Sensei Biotherapeutics Price Target Maintained With a $55.00/Share by BTIG

Dow Jones
·
Jun 16

Sensei Biotherapeutics changes name to Faeth Therapeutics, adopts ticker FTH

Reuters
·
Jun 15

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing Piktor, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

THOMSON REUTERS
·
Jun 15

Sensei Biotherapeutics - Appoints Anand Parikh as Chairman, President and CEO Effective June 12, 2026

THOMSON REUTERS
·
Jun 15

Sensei Biotherapeutics - Piktor Phase 1B/2 Interim Data in Hr+/Her2- Advanced Breast Cancer Expected in 2027

THOMSON REUTERS
·
Jun 15

Sensei Biotherapeutics - Appoints Brian Stephenson as Chief Financial Officer

THOMSON REUTERS
·
Jun 15